 |
|
|
| |
(HepDart) Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients
|
| |
| |
Reported by Jules Levin
A Luetkemeyer1, C Cooper2, P Kwo3, K Kowdley4, S Naik5, M Natha5, LM Stamm5, DM Brainard5, M Sulkowski6, S Naggie7
1San Francisco General Hospital, San Francisco, CA; 2The Ottawa Hospital and Regional Hepatitis Program, Ottawa, ON; 3Indiana University, Division of Gastroenterology/Hepatology, Indianapolis, IN; 4Swedish Liver Center, Department of Gastroenterology/Hepatology, Seattle, WA;
5Gilead Sciences, Inc., Foster City, CA; 6Johns Hopkins University School of Medicine, Baltimore, MD; 7Duke Clinical Research Institute, Infectious Diseases Research, Durham, NC
AASLD: Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiretroviral Regimens in Subjects With HCV/HIV Coinfection - (11/16/15)
CROI: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4- (02/27/15)
|
| |
|
|
|
|
|
